Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Evidence for a hyperglycaemia-dependent decrease of antithrombin III-thrombin complex formation in humans.

A Ceriello1, D Giugliano, A Quatraro

  • 1Cattedra di Diabetologia e Dietoterapia, I Facoltà di Medicina, Università di Napoli, Italy.

Diabetologia
|March 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A prediction model to assess the risk of egfr loss in patients with type 2 diabetes and preserved kidney function: The amd annals initiative.

Diabetes research and clinical practice·2022
Same author

COVID-19 in people living with diabetes: An international consensus.

Journal of diabetes and its complications·2020
Same author

Triple-layer Mesh Plasty for Re-recurrent Ventral Hernia in a Liver Transplant Patient: A Case Report.

Transplantation proceedings·2019
Same author

Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus.

Diabetes & metabolism·2017
Same author

Back to glycemic control: An alternative look at the results of cardiovascular outcome trials in type 2 diabetes.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2017
Same author

Welcome to the 9th Annual meeting of the Diabetes & Cardiovascular disease.

Diabetes & metabolism·2016

Hyperglycaemia in diabetes mellitus reduces antithrombin III activity, leading to increased thrombin hyperactivity. Restoring normal blood sugar or administering heparin can reverse these effects, highlighting the role of glucose control in managing coagulation.

Area of Science:

  • Biochemistry
  • Hematology
  • Endocrinology

Background:

  • Diabetic patients exhibit altered coagulation markers, including increased fibrinopeptide A and decreased antithrombin III activity and thrombin-antithrombin III complex levels.
  • Hyperglycaemia is implicated in the dysregulation of coagulation pathways observed in diabetes mellitus.

Purpose of the Study:

  • To investigate the impact of induced hyperglycaemia and subsequent euglycaemia on coagulation parameters in diabetic and normal subjects.
  • To determine the role of antithrombin III activity in hyperglycaemia-induced thrombin hyperactivity in diabetes mellitus.
  • To evaluate the therapeutic potential of heparin in modulating these coagulation changes.

Main Methods:

  • Induction of hyperglycaemia in diabetic and normal subjects.

Related Experiment Videos

  • Measurement of plasma levels of fibrinopeptide A, antithrombin III activity, and thrombin-antithrombin III complex.
  • Induction of euglycaemia using insulin infusion in diabetic patients.
  • Administration of heparin to assess its effects on coagulation parameters.

    • Main Results:

    • Induced hyperglycaemia decreased antithrombin III activity and thrombin-antithrombin III levels while increasing fibrinopeptide A, without altering antithrombin III concentration.
    • Heparin administration mitigated these hyperglycaemia-induced changes.
    • Insulin-induced euglycaemia in diabetic patients normalized antithrombin III activity, thrombin-antithrombin III complex, and fibrinopeptide A levels.
    • Heparin administration yielded similar beneficial effects on coagulation parameters.

    Conclusions:

    • Hyperglycaemia-dependent decrease in antithrombin III activity plays a crucial role in precipitating thrombin hyperactivity in diabetes mellitus.
    • Maintaining euglycaemia or using heparin can effectively counteract the pro-coagulant state associated with hyperglycaemia in diabetes.
    • These findings underscore the importance of glucose control in managing thrombotic risks in diabetic patients.